E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 2/6/2012 in the Prospect News PIPE Daily.

Northwest Biotherapeutics settles $1.61 million sale of convertibles

Biotech firm sells promissory notes at 10% original issue discount

By Devika Patel

Knoxville, Tenn., Feb. 6 - Northwest Biotherapeutics, Inc. completed a $1.61 million private placement of three secured convertible promissory notes on Jan. 31, according to an 8-K filed Monday with the Securities and Exchange Commission. The initial note has a $605,000 principal, the second note has a principal of $200,000 and the third note's principal is $802,000.

The first and second notes were issued at an original issue discount of 10% and will accrue interest at 6% per year. The third note also has an original issue discount of 10% and carries a 9% coupon.

The first two notes convert to common shares at a price equal to 95% of the average of the daily volume-weighted price of the stock at the time of conversion.

The third note attributed $220,000 of the proceeds as a payment in lieu of the company drawing upon an earlier convertible obligation of $666,666, which would have carried a 40% discount to the market price upon conversion.

The note also allows for an additional $500,000 advance. The conversion price for the $500,000 tranche is equal to 80% of the market price at the time of conversion. The conversion price for the $220,000 tranche is equal to 85% of the market price at the time of conversion.

The first note was sold to Toucan Partners. These notes include 100% warrant coverage.

Northwest is a development-stage biotechnology company based in Bothell, Wash.

Issuer:Northwest Biotherapeutics, Inc.
Issue:Secured convertible promissory notes
Amount:$1,607,000
Price:90
Settlement date:Jan. 31
Stock symbol:OTCBB: NWBO
Stock price:$0.37 at close Jan. 31
Market capitalization:$53.89 million
First note
Amount:$605,000
Coupon:6%
Conversion price:95% of the market price at the time of conversion
Warrants:100% coverage
Investor:Toucan Partners
Second note
Amount:$200,000
Conversion price:95% of the market price at the time of conversion
Coupon:6%
Warrants:No
Third note
Amount:$802,000
Conversion price:80% of the market price at the time of conversion (for $500,000), 85% of market price (for $220,000)
Coupon:9%
Warrants:No

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.